Ask AI
Pharmacist Support in RR CLL

CE

Pharmacist-Led Support in Relapsed/Refractory CLL

Pharmacists: 0.25 contact hour (0.025 CEUs)

Released: June 29, 2026

Expiration: December 28, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

For a patient with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) who is choosing between continuous oral therapy and a fixed-duration venetoclax-based regimen, which patient-centered factor should be discussed to support quality of life and engagement in care?

2.

Based on the BRUIN CLL-321 trial, which counseling point best reflects the clinical implication of pirtobrutinib for this patient?